Laidlaw lowered the firm’s price target on Beyond Air (XAIR) to $5 from $8 and keeps a Buy rating on the shares following the fiscal Q2 report. The firm says Beyond Air is at the early execution stage of LungFit PH commercialization by the new commercial team. It expects more significant sales starting in 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR: